APM
Avidity Partners Management Portfolio holdings
AUM
$499M
This Quarter Return
+7.36%
1 Year Return
+3.47%
3 Year Return
+181.12%
5 Year Return
+409%
10 Year Return
–
AUM
$499M
AUM Growth
+$499M
(+2.9%)
Cap. Flow
+$5.91M
Cap. Flow
% of AUM
1.19%
Top 10 Holdings %
Top 10 Hldgs %
49.06%
Holding
80
New
17
Increased
18
Reduced
13
Closed
25
Top Buys
| 1 |
HNGE
Hinge Health, Inc.
HNGE
|
$16.7M |
| 2 |
Intuitive Surgical
ISRG
|
$14.7M |
| 3 |
Natera
NTRA
|
$13.5M |
| 4 |
CG Oncology
CGON
|
$13.5M |
| 5 |
Genmab
GMAB
|
$13.4M |
Top Sells
| 1 |
Regeneron Pharmaceuticals
REGN
|
$16.1M |
| 2 |
Glaukos
GKOS
|
$13.2M |
| 3 |
Humana
HUM
|
$13.1M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$9.93M |
| 5 |
Neurocrine Biosciences
NBIX
|
$9.48M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Beam Therapeutics
BEAM
$1.66B
| $6.96M | 1.39% | 409,400 -300,117 | -42% | -$5.1M |
|
|
27
Humana
HUM
$36.5B
| $6.75M | 1.34% | 27,600 -53,400 | -66% | -$13.1M |
|
28
Perspective Therapeutics
CATX
$250M
| $6.39M | 1.27% | 1,858,596 -338,674 | -15% | -$1.17M |
|
29
Organon & Co
OGN
$2.45B
| $6.2M | 1.23% | 640,000 +105,000 | +20% | +$1.02M |
|
30
BridgeBio Pharma
BBIO
$9.89B
| $6.05M | 1.2% | 140,000 +65,000 | +87% | +$2.81M |
|
31
Insmed
INSM
$28.8B
| $5.94M | 1.18% | 59,000 -48,000 | -45% | -$4.83M |
|
32
Madrigal Pharmaceuticals
MDGL
$9.76B
| $5.75M | 1.15% | +19,000 | New | +$5.75M |
|
33
Ultragenyx Pharmaceutical
RARE
$2.89B
| $5.6M | 1.12% | 154,000 -168,100 | -52% | -$6.11M |
|
34
Context Therapeutics
CNTX
$75.4M
| $4.9M | 0.98% | 7,477,255 +55 | +0% | +$36 |
|
|
ORKA
35
Oruka Therapeutics, Inc. Common Stock
ORKA
$554M
| $3.95M | 0.79% | 352,124 | – | – |
|
36
Immunic
IMUX
$80.9M
| $3.92M | 0.78% | 5,615,811 +1,161,403 | +26% | +$810K |
|
37
Arcutis Biotherapeutics
ARQT
$1.86B
| $3.76M | 0.75% | +268,000 | New | +$3.76M |
|
38
Doximity
DOCS
$12.7B
| $3.68M | 0.73% | 60,000 -62,500 | -51% | -$3.83M |
|
39
Xenon Pharmaceuticals
XENE
$2.98B
| $3.38M | 0.67% | 107,891 -121,109 | -53% | -$3.79M |
|
|
VRNA
40
Verona Pharma
VRNA
$9.16B
| $3.2M | 0.64% | +33,800 | New | +$3.2M |
|
41
uniQure
QURE
$896M
| $2.89M | 0.57% | 207,000 -129,200 | -38% | -$1.8M |
|
42
Apogee Therapeutics
APGE
$2.17B
| $2.82M | 0.56% | +65,000 | New | +$2.82M |
|
43
Soleno Therapeutics
SLNO
$3.6B
| $2.68M | 0.53% | 32,000 | – | – |
|
44
Cardinal Health
CAH
$35.5B
| $2.52M | 0.5% | +15,000 | New | +$2.52M |
|
45
ARS Pharmaceuticals
SPRY
$1.15B
| $2.44M | 0.49% | +140,000 | New | +$2.44M |
|
46
Kezar Life Sciences
KZR
$28.9M
| $2.3M | 0.46% | 502,600 | – | – |
|
47
Intellia Therapeutics
NTLA
$1.22B
| $2.18M | 0.43% | +232,000 | New | +$2.18M |
|
48
MoonLake Immunotherapeutics
MLTX
$3.54B
| $1.84M | 0.37% | +39,000 | New | +$1.84M |
|
49
Arvinas
ARVN
$568M
| $1.79M | 0.36% | 243,162 -170,000 | -41% | -$1.25M |
|
50
Syndax Pharmaceuticals
SNDX
$1.41B
| $1.4M | 0.28% | 150,000 -775,000 | -84% | -$7.26M |
|